Zhejiang Supor Pharmaceuticals is an API manufacturer based in China. It holds 20 active US drug master files across a filed portfolio of 19 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3005183062 |
| Molecule | Regulators | Docs |
|---|---|---|
| Bupropion | US FDA | 2 |
| Tinidazole | SFDA (Saudi Arabia), US FDA | 2 |
| Apixaban | US FDA | 1 |
| Edoxaban | US FDA | 1 |
| Felodipine | US FDA | 1 |
| Hydroxychloroquine | US FDA | 1 |
| Lamotrigine | US FDA | 1 |
| Linaclotide | US FDA | 1 |
| Linezolid | US FDA | 1 |
| Memantine | US FDA | 1 |
| Mitotane | US FDA | 1 |
| Olanzapine | US FDA | 1 |
| Quetiapine | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Rizatriptan | US FDA | 1 |
| Saxagliptin | US FDA | 1 |
| Secnidazole | US FDA | 1 |
| Tenofovir Disoproxil | US FDA | 1 |
| Ticagrelor | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Supor Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free